Skip to content

CNC

Centene Corporation

NYSE · Healthcare · Medical - Healthcare Plans · US

$67.04
−1.44%
Ask drillr

Research · Sep 3, 2026

[CNC] Centene Thesis 2026: Marketplace Repricing Restores Earnings Floor After Guidance Reset

Centene FY25 revenue $194.78B (+19%); op income -$7.62B (vs +$3.18B FY24); NI -$6.67B; EPS -$13.62. Adj EPS ~$2 (vs $6.31 FY24) reflects Marketplace morbidity shift + Medicaid trend pressure. Q2 alone $2.4B pretax morbidity headwind. Q4 Medicaid HBR 93.0% (-190bp from Q2 peak 94.9%). Marketplace 5.8M Q3 → repriced 95%+ for FY26 (3.5M expected by Q1 FY26 after eAPTC expiration). Medicare Advantage on track for 2027 breakeven. FY26 guide: adj EPS >$3 (+40% YoY); premium + service revenue $170-$174B; Medicaid member months -5-6%; Marketplace -$8B revenue; Medicare +$7.5B; consolidated HBR 90.9-91.7% (-60bp midpoint).

Research · Apr 9, 2026

Medicare Advantage 2026 Rate Hike: UNH and HUM Lead Margin Winners — Ranked

The April 7, 2026, Medicare Advantage rate decision sparked gains for UNH and HUM, signaling margin relief for exposed insurers. UNH leads with balanced exposure and scale, followed by HUM's pure-play bet and CI's value. Rankings prioritize MA leverage, growth, and valuations amid stabilizing reimbursements.